The Aspirin Dilemma: ATTACK Trial Challenges Primary Prevention Paradigm in Chronic Kidney Disease

DENVER — For over a century, aspirin has been the cornerstone of cardiovascular medicine. Since its commercial debut in 1899, the antiplatelet agent has been lauded for its ability to prevent recurrent heart attacks and strokes. Yet, as medical science advances, the role of aspirin in "primary prevention"—treating patients who have not yet suffered a cardiovascular event—remains one of the most contentious topics in cardiology and nephrology.

New data presented at the American Society of Nephrology (ASN) Kidney Week annual meeting in Denver has shed fresh light on this debate, specifically concerning the high-risk population of patients with chronic kidney disease (CKD). The randomized, multicenter ATTACK trial, which investigated the use of daily low-dose aspirin in these patients, failed to reach its primary endpoint, leaving clinicians with more questions than answers regarding the risk-benefit profile of the drug.

Main Facts: The ATTACK Trial Findings

The ATTACK trial (Aspirin to Target Arterial Events in Chronic Kidney Disease) was designed as a pragmatic, open-label study to determine whether daily low-dose aspirin (75 mg) could reduce major vascular events in patients with stage 1 to 4 CKD who had no history of cardiovascular disease.

Over a mean follow-up period of 3.1 years, researchers monitored a composite primary endpoint consisting of non-fatal myocardial infarction (MI), non-fatal stroke, or cardiovascular death. The results were sobering: 2.4% of patients in the aspirin group experienced a major vascular event, compared to 3.3% in the control group. While the trend favored aspirin, the difference did not reach statistical significance (Hazard Ratio [HR] 0.73, 95% CI 0.52-1.03, P=0.077).

However, a closer examination of the individual components of the primary endpoint revealed a silver lining: non-fatal stroke. Aspirin therapy was associated with a statistically significant reduction in the risk of non-fatal stroke (HR 0.51, 95% CI 0.29-0.90, P=0.021). Despite this specific benefit, the trial’s failure to achieve the composite primary endpoint means that current clinical guidelines for primary prevention in CKD remain unchanged.

Chronology: A Century of Aspirin and the Evolution of the Trial

To understand the weight of the ATTACK findings, one must look at the long trajectory of aspirin use. For decades, the medical community operated under the assumption that aspirin’s blood-thinning properties were universally beneficial for those at risk of clotting. However, recent years have seen a paradigm shift, particularly with the publication of the ARRIVE, ASCEND, and ASPREE trials, which collectively demonstrated that for many elderly or low-to-moderate risk populations, the risk of gastrointestinal or intracranial bleeding often negates the cardiovascular benefits.

The ATTACK trial was initiated to see if this "delicate balance" of harm and benefit shifted when applied to CKD patients. This population is unique; they carry an exceptionally high burden of cardiovascular disease, with approximately 100,000 heart attacks and strokes occurring annually in the U.K. alone among individuals with stage 3 to 5 CKD.

The trial’s progression, however, was hampered by the global COVID-19 pandemic. Originally aiming to enroll 25,000 participants, the study was forced to conclude with 4,633 participants. This reduction in sample size significantly impacted the trial’s statistical power, a limitation that lead investigator Hugh Gallagher, MBBS, PhD, of Epsom and St Helier University Hospitals NHS Trust, openly acknowledged during the presentation in Denver.

Supporting Data: The Balancing Act of Bleeding vs. Protection

The central tension in the ATTACK trial—and in primary prevention studies generally—is the trade-off between antiplatelet protection and hemorrhagic risk. In secondary prevention (patients who have already had a heart attack or stroke), the argument for aspirin is settled: the reduction in recurrent events far outweighs the risk of bleeding.

In the primary prevention setting, however, the benefit is much smaller. As Gallagher explained, in the general population, a 0.4% absolute reduction in cardiovascular events is often canceled out by a 0.4% increase in bleeding risks. Because CKD patients already suffer from uremic platelet dysfunction and systemic inflammation, they are inherently more prone to bleeding, making the "break-even" point for aspirin much harder to achieve.

Key data points from the ATTACK trial included:

• Study Design: Pragmatic, multicenter, open-label, randomized controlled trial.
• Participant Profile: Mean age of 73; mean estimated glomerular filtration rate (eGFR) of 54 mL/min/1.73 m². The cohort was overwhelmingly white, which may limit the generalizability of the findings to more diverse populations.
• Safety Profile: Encouragingly, the study found no statistically significant differences in secondary safety outcomes, including major hemorrhage or site-specific bleeding events (intracranial or gastrointestinal).

While the lack of increased bleeding in the ATTACK trial is a positive signal, the lack of significant primary outcome improvement suggests that low-dose aspirin may simply be insufficient to alter the complex vascular pathology associated with kidney disease.

Official Responses and Expert Perspective

Dr. Gallagher’s presentation was met with tempered expectations from the nephrology community. "We’re not in a place where we should be offering aspirin for primary prevention at this stage, but the question still needs answering," Gallagher noted. His stance reflects a growing consensus in evidence-based medicine: when in doubt, "do no harm" by avoiding unnecessary chronic medications.

Experts at the ASN meeting noted that while the reduction in non-fatal stroke was intriguing, it was a "secondary observation" within a failed primary endpoint. In clinical research, such findings are typically categorized as hypothesis-generating rather than practice-changing. The consensus among those attending the sessions was that until more robust data is available, nephrologists should stick to established secondary prevention protocols and focus on other established cardiovascular risk factors, such as blood pressure management, statin therapy, and the use of SGLT2 inhibitors, which have shown significant cardiorenal benefits in recent years.

Implications: Where Does Nephrology Go From Here?

The primary implication of the ATTACK trial is the continued absence of a definitive guideline for primary cardiovascular prevention in CKD. As the medical community looks forward, the focus is shifting from individual trials to collaborative, large-scale synthesis of data.

Gallagher confirmed that the research team is currently working with the Antithrombotic Trialists’ Collaboration. Their goal is to pool the ATTACK data with other existing studies to produce an individual participant data (IPD) meta-analysis. This statistical technique allows researchers to combine data from multiple trials to gain a clearer picture of the treatment effect, potentially providing the statistical power that the individual studies—including ATTACK—lacked.

For the practicing clinician, the message is clear:

1. Maintain Secondary Prevention: Aspirin remains vital for patients with established cardiovascular disease, regardless of their CKD status.
2. Exercise Caution in Primary Prevention: Without further evidence, routine aspirin use for the sole purpose of primary cardiovascular prevention in CKD patients cannot be recommended.
3. Prioritize Proven Interventions: Given the high burden of disease in the CKD population, clinicians should focus on interventions with clear, evidence-based survival benefits, such as optimizing RAAS inhibition and managing comorbid metabolic conditions.

The ATTACK trial, while falling short of its ambitious primary goals, serves as a vital piece of the puzzle. It reminds us that 130 years after its commercial introduction, aspirin remains a complex tool. The path forward requires not just more trials, but more integrated, patient-centered research that accounts for the unique vulnerabilities of the kidney disease population. As the medical community awaits the upcoming meta-analysis, the standard of care remains anchored in the proven—and wary of the unverified.